Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galeterone Combined With Gemcitabine in Advanced Pancreatic Adenocarcinoma
NCT04098081Phase 2Active, not recruiting
- Sponsor
- University of Maryland, Baltimore
- Start
- Dec 2019
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of galeterone in pancreatic adenocarcinoma (PDAC), sponsored by University of Maryland, Baltimore. Started Dec 2019; status: active, not recruiting.
02
Drugs
galeterone
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04098081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04098081.